HUP0102839A2 - Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítmények - Google Patents
Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0102839A2 HUP0102839A2 HU0102839A HUP0102839A HUP0102839A2 HU P0102839 A2 HUP0102839 A2 HU P0102839A2 HU 0102839 A HU0102839 A HU 0102839A HU P0102839 A HUP0102839 A HU P0102839A HU P0102839 A2 HUP0102839 A2 HU P0102839A2
- Authority
- HU
- Hungary
- Prior art keywords
- hypertension
- syndrome
- cys
- pancreatic
- lanreotide
- Prior art date
Links
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 title 1
- 229960002437 lanreotide Drugs 0.000 title 1
- 108010021336 lanreotide Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 229940075620 somatostatin analogue Drugs 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 201000000052 gastrinoma Diseases 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 206010003445 Ascites Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 208000014311 Cushing syndrome Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000037147 Hypercalcaemia Diseases 0.000 abstract 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 abstract 1
- 201000002980 Hyperparathyroidism Diseases 0.000 abstract 1
- 208000010191 Osteitis Deformans Diseases 0.000 abstract 1
- 208000027868 Paget disease Diseases 0.000 abstract 1
- 206010033635 Pancreatic pseudocyst Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010039710 Scleroderma Diseases 0.000 abstract 1
- 206010041101 Small intestinal obstruction Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 abstract 1
- 208000009311 VIPoma Diseases 0.000 abstract 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- 150000001945 cysteines Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010060865 duodenogastric reflux Diseases 0.000 abstract 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 abstract 1
- 230000000148 hypercalcaemia Effects 0.000 abstract 1
- 208000030915 hypercalcemia disease Diseases 0.000 abstract 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 abstract 1
- 201000008980 hyperinsulinism Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 208000027202 mammary Paget disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 206010027191 meningioma Diseases 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000007232 portal hypertension Diseases 0.000 abstract 1
- 230000000291 postprandial effect Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány tárgya H-b-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys- Thr-NH2 - aképletben a két cisztein diszulfidkötéssel kapcsolódik - vagy valamelygyógyszerészetileg elfogadható sója alkalmazása az alábbi betegségekvagy állapotok kezelésére alkalmas gyógyszerkészítményekelőállítására: szisztémás sclerosis, hasnyálmirigy pszeudociszták,hasnyálmirigy hasvízkór, VIPoma, nesidoblastosis, hyperinsulinémia,gastrinoma, Zollinger-Ellison szindróma, hyperszekréciós hasmenés,scleroderma, irritálható bél szindróma, felső gastrointestinálisvérzés, postprandialis venae portae hypertensio, portalishypertensioval összefüggő komplikációk, vékonybél elzáródás, duodeno-gyomor reflux, Cushing-féle szindróma, gonadotropinoma,hyperparathyroidismus, diabeteszes neuropathya, maculás degeneráció,rosszindulatú hypercalcemia, Paget-féle betegség, meningioma, rákoscachexia, psoriasis, hypertensio és pánik rohamok. A találmány tárgyamég a fenti vegyületet tartalmazó gyógyszerkészítmény. Ó
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9469398P | 1998-07-30 | 1998-07-30 | |
| US12652598A | 1998-07-30 | 1998-07-30 | |
| PCT/US1999/017294 WO2000006185A2 (en) | 1998-07-30 | 1999-07-29 | Methods of using lanreotide, a somatostatin analogue |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0102839A2 true HUP0102839A2 (hu) | 2002-01-28 |
| HUP0102839A3 HUP0102839A3 (en) | 2002-02-28 |
Family
ID=26789150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0102839A HUP0102839A3 (en) | 1998-07-30 | 1999-07-29 | Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1100532A2 (hu) |
| JP (1) | JP2002521456A (hu) |
| KR (1) | KR20010071071A (hu) |
| CN (1) | CN1334742A (hu) |
| AR (1) | AR023633A1 (hu) |
| AU (2) | AU770193B2 (hu) |
| BR (1) | BR9912609A (hu) |
| CA (1) | CA2335654A1 (hu) |
| CZ (1) | CZ2001157A3 (hu) |
| HU (1) | HUP0102839A3 (hu) |
| IL (2) | IL140837A0 (hu) |
| MX (1) | MXPA01000969A (hu) |
| NO (1) | NO324123B1 (hu) |
| NZ (1) | NZ509348A (hu) |
| PL (1) | PL346361A1 (hu) |
| WO (1) | WO2000006185A2 (hu) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1040837A3 (en) * | 1999-02-26 | 2002-01-02 | Erasmus Universiteit Rotterdam | Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder |
| AU2001283957A1 (en) * | 2000-07-27 | 2002-02-13 | Novartis Ag | Treatment of ocular disorders with somatostatin analogues |
| US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| ES2345280T3 (es) | 2001-03-06 | 2010-09-20 | The Administrators Of The Tulane Educational Fund | Procedimiento de modulacion de la proliferacion de celulas de carcinoma tiroideo medular. |
| GB0109461D0 (en) * | 2001-04-18 | 2001-06-06 | Univ London | New Gene |
| WO2003061592A2 (en) | 2002-01-22 | 2003-07-31 | New York University | Methods for therapeutic treatment of benign prostatic hypertrophy (bph) |
| CN107446053A (zh) | 2008-06-12 | 2017-12-08 | 益普生生物创新有限公司 | 癌症的抑制 |
| KR101642363B1 (ko) | 2008-06-12 | 2016-07-25 | 입센 바이오이노베이션 리미티드 | 신경내분비계 질환의 억제 |
| GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
| CN101935252B (zh) * | 2010-07-29 | 2013-01-30 | 广东省农业科学院科技情报研究所 | 一种园林植物生长延缓剂及其制备方法 |
| BR112014025058B1 (pt) * | 2012-04-12 | 2022-07-12 | Novartis Ag | Combinação de análogos de somatostatina com inibidores de 11beta-hidroxilase, e seus usos |
| CN105168115A (zh) * | 2015-09-02 | 2015-12-23 | 中国药科大学 | 生长抑素类似物多肽药物的口服给药途径 |
| WO2017212390A1 (en) * | 2016-06-06 | 2017-12-14 | Emcure Pharmaceuticals Ltd, | Process for lanreotide acetate preparation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853371A (en) * | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
| US5538739A (en) * | 1989-07-07 | 1996-07-23 | Sandoz Ltd. | Sustained release formulations of water soluble peptides |
| ATE140237T1 (de) * | 1989-12-08 | 1996-07-15 | Univ Tulane | Oktapeptidanaloge von somatostatin mit threonin in position 6 |
| WO1998008528A1 (en) * | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
| WO1998010786A2 (en) * | 1996-09-12 | 1998-03-19 | Yarom Cohen | Pharmaceutical composition for the treatment of syndrome x of reaven |
| DE69822810T2 (de) * | 1997-05-13 | 2005-02-03 | Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. | Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x |
-
1999
- 1999-07-29 NZ NZ509348A patent/NZ509348A/xx unknown
- 1999-07-29 AU AU52447/99A patent/AU770193B2/en not_active Ceased
- 1999-07-29 CN CN99808953A patent/CN1334742A/zh active Pending
- 1999-07-29 WO PCT/US1999/017294 patent/WO2000006185A2/en not_active Application Discontinuation
- 1999-07-29 CA CA002335654A patent/CA2335654A1/en not_active Abandoned
- 1999-07-29 KR KR1020017001277A patent/KR20010071071A/ko not_active Application Discontinuation
- 1999-07-29 CZ CZ2001157A patent/CZ2001157A3/cs unknown
- 1999-07-29 MX MXPA01000969A patent/MXPA01000969A/es unknown
- 1999-07-29 HU HU0102839A patent/HUP0102839A3/hu unknown
- 1999-07-29 BR BR9912609-5A patent/BR9912609A/pt not_active IP Right Cessation
- 1999-07-29 PL PL99346361A patent/PL346361A1/xx unknown
- 1999-07-29 AR ARP990103765A patent/AR023633A1/es unknown
- 1999-07-29 JP JP2000562039A patent/JP2002521456A/ja active Pending
- 1999-07-29 IL IL14083799A patent/IL140837A0/xx unknown
- 1999-07-29 EP EP99937658A patent/EP1100532A2/en not_active Withdrawn
-
2001
- 2001-01-29 NO NO20010481A patent/NO324123B1/no not_active IP Right Cessation
-
2004
- 2004-04-29 AU AU2004201783A patent/AU2004201783A1/en not_active Abandoned
-
2007
- 2007-02-15 IL IL181349A patent/IL181349A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ2001157A3 (cs) | 2002-02-13 |
| PL346361A1 (en) | 2002-02-11 |
| AR023633A1 (es) | 2002-09-04 |
| IL181349A0 (en) | 2007-07-04 |
| KR20010071071A (ko) | 2001-07-28 |
| MXPA01000969A (es) | 2003-04-07 |
| AU770193B2 (en) | 2004-02-12 |
| NO20010481L (no) | 2001-03-21 |
| WO2000006185A2 (en) | 2000-02-10 |
| HUP0102839A3 (en) | 2002-02-28 |
| CN1334742A (zh) | 2002-02-06 |
| BR9912609A (pt) | 2001-05-02 |
| JP2002521456A (ja) | 2002-07-16 |
| AU2004201783A1 (en) | 2004-05-27 |
| NZ509348A (en) | 2004-02-27 |
| IL140837A0 (en) | 2002-02-10 |
| WO2000006185A3 (en) | 2000-08-03 |
| NO324123B1 (no) | 2007-08-27 |
| AU5244799A (en) | 2000-02-21 |
| NO20010481D0 (no) | 2001-01-29 |
| EP1100532A2 (en) | 2001-05-23 |
| CA2335654A1 (en) | 2000-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0102839A2 (hu) | Lanreotide-szomatosztatin analóg alkalmazása gyógyszerkészítmények előállítására és az azt tartalmazó gyógyszerkészítmények | |
| KR100393701B1 (ko) | 치환된옥사졸리딘칼파인및/또는카텝신b억제제및이를포함하는약제학적조성물 | |
| AU637882B2 (en) | The use of guanidine derivatives for the preparation of a pharmaceutical product having pny antagonistic activity | |
| KR100809205B1 (ko) | 비아릴옥시메틸아렌-카복실산 | |
| US11767311B2 (en) | Acid secretion inhibitor and use thereof | |
| NZ199990A (en) | 1,4-dihydropyridine derivatives and pharmaceutical compositions | |
| ATE396190T1 (de) | Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase | |
| KR860001921B1 (ko) | 1,4-디하이드로피리딘의 제조방법 | |
| KR950010326B1 (ko) | 신규의 이미다졸릴구아니딘 유도체와 그 제법 | |
| DE2949491A1 (de) | 1,4-dihydropyridine, ihre herstellung und verwendung | |
| KR840001075B1 (ko) | 티아졸 유도체의 제조방법 | |
| CA1296716C (en) | N-(2-substituted alkyl)-n'-[(imidazole-4-yl) alkyl] guanidine | |
| US20040038990A1 (en) | Aminothiazole derivatives | |
| CN1307166C (zh) | HPPAR－α受体的噁唑/噻唑衍生物活化剂 | |
| JP2755385B2 (ja) | ニトロエテン誘導体の製造法 | |
| JPS5835185A (ja) | ３−メチルフラボン−８−カルボン酸エステル類 | |
| US4994476A (en) | Dihydropyridin-3,5-dicarboxylates incorporating aryloxypropanolamine moieties | |
| ZA200305100B (en) | 2-Arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof. | |
| DE60227421D1 (de) | Rmazeutische zusammensetzung und verwendung davon | |
| IL292684A (en) | A polypeptide with mmp2 inhibitory effect | |
| WO2005048916A3 (en) | Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders | |
| KR880002209B1 (ko) | 치환된 3,4-디아미노-1,2,5-티아디아졸류 및 그의 제조방법 | |
| US6906166B2 (en) | Polymers and oligomers, their synthesis, and electronic devices incorporating same | |
| DE69300318T2 (de) | Flavonderivate. | |
| RU2001105926A (ru) | Способы применения аналога соматостатина |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |